Therefore, direct neutralization of IL-6R and cofactor gp130 may offer therapeutic potential in CKD, however, questions remain into how effective these prospective treatments may be in downstream IL-6 effects, such as FGF23 and aldosterone attenuation. Here, FGF23 is linked to chronic kidney disease.